Drug updated on 11/14/2023
| Dosage Form | Pellet (oral; 200 mcg, 600 mcg); Capsule (oral; 400 mcg, 1200 mcg) |
| Drug Class | Ileal bile acid transporter inhibitors |
| System | Digestive |
Indication
- For the treatment of pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC).
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Bylavy (odevixibat) Prescribing Information. | 2021 | Albireo Pharma Inc., Boston, MA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Odevixibat for treating progressive familial intrahepatic cholestasis. | 2022 | NICE |
| Ileal bile acid transporter blockers for cholestatic liver disease in pediatric patients with alagille syndrome: a systematic review and meta-analysis. | 2022 | Journal of Clinical Medicine |
| Assessment report: Bylvay. | 2021 | EMA |
Ongoing and completed studies: ClinicalTrials.gov